Background
Methods
Type of study
Population studied
Participating facilities
Study period
Study variables
Procedure
Statistical analysis
Results
Diagnostic group | Total frequency | Frequency by group | ||
---|---|---|---|---|
n | % | n | % | |
I. Leukemias
|
784
|
46.1
|
784
|
100.0
|
IA. Acute lymphoblastic leukemia | 614 | 36.1 | 614 | 78.3 |
IB. Acute non-lymphoblastic leukemia | 146 | 8.6 | 146 | 18.6 |
CI. Chronic myeloid leukemia | 16 | 1.0 | 16 | 2.0 |
ID. Other specific leukemias | 4 | 0.2 | 4 | 0.5 |
IE. Nonspecific leukemias | 4 | 0.2 | 4 | 0.5 |
II. Lymphomas*
|
194
|
11.4
|
194
|
100.0
|
IIA. Hodgkin disease | 65 | 3.8 | 65 | 33.5 |
IIB. Non-Hodgkin lymphoma | 104 | 6.1 | 104 | 53.6 |
IIC. Burkitt lymphoma | 21 | 1.2 | 21 | 10.8 |
IIE. Nonspecific lymphomas | 4 | 0.2 | 4 | 2.1 |
III. Central Nervous System Tumors
|
197
|
11.6
|
197
|
100.0
|
IIIA. Ependymoma | 29 | 1.7 | 29 | 14.7 |
IIIB. Astrocytoma | 97 | 5.7 | 97 | 49.2 |
IIIC. Primitive neuroectodermal tumors | 52 | 3.1 | 52 | 26.4 |
IIID. Other gliomas | 9 | 0.5 | 9 | 4.6 |
IIIE. Other specific intracranial and intraspinal neoplasms | 9 | 0.5 | 9 | 4.6 |
IIIF. Other nonspecific intracranial and intraspinal neoplasms | 1 | 0.1 | 1 | 0.5 |
IV. Symphatetic Nervous System Tumors
|
39
|
2.3
|
39
|
100.0
|
IVA1. Ganglioneuroblastoma | 6 | 0.3 | 6 | 15.4 |
IVA2. Neuroblastoma | 30 | 1.7 | 30 | 76.9 |
IVB1. Meduloepitelioma | 1 | 0.1 | 1 | 2.6 |
IVB3. Neuroepithelioma | 1 | 0.1 | 1 | 2.6 |
IVB4. Olfactory neuroblastoma | 1 | 0.1 | 1 | 2.6 |
V. Retinoblastoma
|
73
|
4.3
|
73
|
100.0
|
V1. Retinoblastoma | 46 | 2.7 | 46 | 63.0 |
V2. Differentiated retinoblastoma | 24 | 1.4 | 24 | 32.9 |
V3. Undifferentiated retinoblastoma | 3 | 0.2 | 3 | 4.1 |
VI. Renal Tumors
|
71
|
4.2
|
71
|
100.0
|
VIA1. Nephroblastoma | 62 | 3.6 | 62 | 87.3 |
VIA2. Rabdoid sarcoma | 2 | 0.2 | 2 | 2.8 |
VIA3. Clear-cell sarcoma | 6 | 0.3 | 6 | 8.5 |
VIB. Renal Carcinoma | 1 | 0.1 | 1 | 1.4 |
VII. Hepatic Tumors
|
30
|
1.8
|
30
|
100.0
|
VIIA. Hepatoblastoma | 26 | 1.5 | 26 | 86.7 |
VIIB1. Hepatic carcinoma | 1 | 0.1 | 1 | 3.3 |
VIIB2. Hepatic carcinoma undifferentiated | 1 | 0.1 | 1 | 3.3 |
VIIB3. Neuroendocrine carcinoma | 1 | 0.1 | 1 | 3.3 |
VIIB4. Acinar adenocarcinoma | 1 | 0.1 | 1 | 3.3 |
VIII. Bone Tumors
|
97
|
5.7
|
97
|
100.0
|
VIIIA. Osteosarcoma | 70 | 4.1 | 70 | 72.2 |
VIIIB. Chondrosarcoma | 4 | 0.2 | 4 | 4.1 |
VIIIC. Ewing sarcoma | 18 | 1.1 | 18 | 18.6 |
VIIID. Other specific malignant tumors | 3 | 0.2 | 3 | 3.1 |
VIIIE. Unspecified malignant bone tumors | 2 | 0.2 | 2 | 2.1 |
IX. Soft-Tissue Sarcomas
|
89
|
5.2
|
89
|
100.0
|
IXA. Rhabdomyosarcoma and embryonal sarcoma | 49 | 2.9 | 49 | 55.1 |
IXB. Fibrosarcoma, neurofibrosarcoma and others fibromatous neoplasms | 21 | 1.2 | 21 | 23.6 |
IXD. Other specific soft tissue sarcomas | 17 | 1.0 | 17 | 19.1 |
IXE. Unspecified soft tissue sarcomas | 2 | 0.2 | 2 | 2.2 |
X. Germ Cell Tumors
|
110
|
6.5
|
110
|
100.0
|
XA. Intracranial and intraspinal germ cell tumors | 15 | 0.9 | 15 | 13.6 |
XB. Other and unspecified non-gonadal germ cell tumors | 13 | 0.8 | 13 | 11.8 |
XC. Gonadal germ cell tumors | 80 | 4.7 | 80 | 72.7 |
XD. Gonadal carcinomas | 2 | 0.2 | 2 | 1.8 |
XI. Carcinomas
|
18
|
1.1
|
18
|
100.0
|
XIA. Adrenocortical carcinoma | 3 | 0.2 | 3 | 16.7 |
XIB. Thyroid carcinoma | 1 | 0.1 | 1 | 5.5 |
XIC. Nasopharyngeal carcinoma | 1 | 0.1 | 1 | 5.5 |
XID. Malignant melanoma | 3 | 0.2 | 3 | 16.7 |
XIE. Skin carcinoma | 3 | 0.2 | 3 | 16.7 |
XIF. Other and unspecified carcinomas | 7 | 0.4 | 7 | 38.9 |
Total
|
1702
|
100.0
|
1702
|
100.0
|
< 1 | 1–4 | 5–9 | 10–14 | Male | Female | Ratio | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Diagnostic group | Age group (years) | Sex | |||||||||||
N
|
%
|
n
|
%
|
n
|
%
|
n
|
%
|
n
|
%
|
n
|
%
|
M/F
| |
I. Leukemias | 24 | 27.9
| 301 | 48.0
| 246 | 50.5
| 213 | 42.4
| 412 | 46.6
| 372 | 45.5
| 1.1 |
II. Lymphomas* | 0 | 0.0 | 49 | 7.8 | 79 | 16.2
| 66 | 13.2
| 138 | 15.6
| 56 | 6.8 | 2.5 |
Hodgkin disease | 0 | 0.0 | 7 | 1.1 | 26 | 5.3 | 32 | 6.4 | 43 | 4.9 | 22 | 2.7 | 1.9 |
Non-Hodgkin lymphoma | 0 | 0.0 | 42 | 6.7 | 53 | 10.9 | 34 | 6.8 | 95 | 10.7 | 34 | 4.1 | 2.8 |
III. CNST | 6 | 7.0 | 69 | 11.0
| 59 | 12.1
| 63 | 12.5 | 84 | 9.5
| 113 | 13.8
| 0.7 |
IV. SNST | 9 | 10.5 | 21 | 3.3 | 5 | 1.0 | 4 | 0.8 | 20 | 2.3 | 19 | 2.3 | 1.1 |
V. Retinoblastoma | 15 | 17.4
| 56 | 8.9
| 1 | 0.2 | 1 | 0.2 | 34 | 3.8 | 39 | 4.8 | 0.9 |
VI. Renal Tumors | 7 | 8.1 | 44 | 7.0 | 15 | 3.1 | 5 | 1.0 | 39 | 4.4 | 32 | 3.9 | 1.2 |
VII. Hepatic Tumors | 7 | 8.1 | 11 | 1.8 | 7 | 1.4 | 5 | 1.0 | 13 | 1.5 | 17 | 2.1 | 0.8 |
VIII. Bone Tumors | 0 | 0.0 | 6 | 1.0 | 26 | 5.3 | 65 | 12.9
| 43 | 4.9 | 54 | 6.6 | 0.8 |
IX. Soft Tissue Sarcomas | 5 | 5.8 | 29 | 4.6 | 23 | 4.7 | 32 | 6.4 | 43 | 4.9 | 46 | 5.6 | 0.9 |
X. Germ Cell Tumors | 13 | 15.1
| 38 | 6.1 | 19 | 3.9 | 40 | 8.0 | 49 | 5.5 | 61 | 7.5
| 0.8 |
XI. Carcinomas | 0 | 0.0 | 3 | 0.5 | 7 | 1.4 | 8 | 1.6 | 9 | 1.0 | 9 | 1.1 | 1.0 |
Total | 86 | 100 | 627 | 100 | 487 | 100 | 502 | 100 | 884 | 100 | 818 | 100 | 1.1 |
Diagnostic group | Chiapas | Mexico City | Guerrero | State of Mexico | Morelos | |||||
---|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | n | % | |
I. Leukemias | 46 | 37.4
| 280 | 43.5
| 33 | 31.7
| 377 | 51.5
| 48 | 48.0
|
II. Lymphomas** | 13 | 10.6
| 83 | 12.9
| 20 | 19.2
| 67 | 9.2
| 11 | 11.0
|
Hodgkin disease | 4 | 3.3 | 21 | 3.3 | 6 | 5.8 | 32 | 4.4 | 2 | 2.0 |
Non-Hodgkin lymphoma | 9 | 7.3 | 62 | 9.6 | 14 | 13.5 | 35 | 4.8 | 9 | 9.0 |
III. CNST | 18 | 14.6
| 85 | 13.2
| 19 | 18.3
| 67 | 9.2
| 8 | 8.0
|
IV. SNST | 1 | 0.8 | 17 | 2.6 | 7 | 6.7
| 12 | 1.6 | 2 | 2.0 |
V. Retinoblastoma | 11 | 8.9
| 22 | 3.4 | 5 | 4.8 | 31 | 4.2 | 4 | 4.0 |
VI. Renal tumors | 4 | 3.3 | 26 | 4.0 | 5 | 4.8 | 30 | 4.1 | 6 | 6.0 |
VII. Hepatic tumors | 3 | 2.4 | 18 | 2.8 | 0 | 0.0 | 8 | 1.1 | 1 | 1.0 |
VIII. Bone tumors | 9 | 7.3
| 31 | 4.8 | 7 | 6.7
| 43 | 5.9
| 7 | 7.0
|
IX. Soft tissue sarcomas | 8 | 6.5 | 35 | 5.4
| 4 | 3.8 | 36 | 4.9 | 6 | 6.0
|
X. Germ cell tumors | 6 | 4.9 | 42 | 6.5
| 2 | 1.9 | 55 | 7.5
| 5 | 5.0 |
XI. Carcinomas | 4 | 3.3 | 4 | 0.6 | 2 | 1.9 | 6 | 0.8 | 2 | 2.0 |
Total | 123 | 100 | 643 | 100 | 104 | 100 | 732 | 100 | 100 | 100 |
Discussion
Diagnostic Group | Mexico City 1980–19919/
| Mexico City 1992–199310/
| Mexico City 1996–2001 | USA-SEER White 1983–19922/
| German Federal Republic 1985–19902/
| France 1983–19923/
| Cuba 1986–19905/
| |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
n | % | n | % | n | % | n | % | n | % | n | % | n | % | |
I. Leukemias | 1706 | 34.9
| 78 | 39.2
| 784 | 46.1
| 1757 | 30.7
| 2422 | 34.4
| 746 | 29.4
| 454 | 30.7
|
II. Lymphomas** | 888 | 18.2
| 34 | 17.6
| 194 | 11.4
| 616 | 10.7
| 781 | 11.1
| 310 | 12.2
| 271 | 18.3
|
Hodgkin disease | 524 | 10.7 | 18 | 9.0 | 65 | 3.8 | 259 | 4.5 | 279 | 4.0 | 103 | 4.1 | 84 | 5.7 |
Non-Hodgkin lymphoma | 364 | 7.5 | 16 | 8.6 | 129 | 7.6 | 357 | 6.2 | 502 | 7.1 | 207 | 8.1 | 187 | 12.6 |
III. CNST | 496 | 10.2
| 25 | 12.6
| 197 | 11.6
| 1222 | 21.4
| 1392 | 19.8
| 538 | 21.2
| 223 | 15.1
|
IV. SNST | 133 | 2.7 | 6 | 3.0 | 39 | 2.3 | 469 | 8.2
| 552 | 7.8
| 244 | 9.6
| 104 | 7.0
|
V. Retinoblastoma | 420 | 8.6
| 5 | 2.5 | 73 | 4.3 | 172 | 3.0 | 208 | 2.9 | 61 | 2.4 | 40 | 2.7 |
VI. Renal Tumors | 279 | 5.7 | 9 | 4.5 | 71 | 4.2 | 366 | 6.4 | 464 | 6.6 | 152 | 5.9 | 69 | 4.7 |
VII. Hepatic Tumors | 70 | 1.4 | 1 | 0.5 | 30 | 1.8 | 83 | 1.5 | 82 | 1.2 | 23 | 0.9 | 21 | 1.4 |
VIII. Bone Tumors | 321 | 6.6
| 9 | 4.5 | 97 | 5.7
| 267 | 4.7 | 359 | 5.1 | 129 | 5.1 | 87 | 5.9 |
IX. Soft Tissue Sarcomas | 238 | 4.9 | 10 | 5.0
| 89 | 5.2 | 387 | 6.8
| 492 | 7.0
| 154 | 6.1
| 91 | 6.2
|
X. Germ Cell Tumors | 256 | 5.2 | 17 | 8.6
| 110 | 6.5
| 165 | 2.9 | 222 | 3.2 | 71 | 2.8 | 34 | 2.3 |
XI. Carcinomas | 55 | 1.1 | 3 | 1.5 | 18 | 1.1 | 193 | 3.4 | 55 | 0.8 | 108 | 4.3 | 55 | 3.7 |
XII. Nonspecific | 18 | 0.4 | 0 | 0 | 0 | 0.0 | 21 | 0.4 | 7 | 0.1 | 2 | 0.1 | 29 | 2.0 |
Total | 4880 | 100 | 198 | 100 | 1702 | 100 | 5718 | 100 | 7036 | 100 | 2538 | 100 | 1478 | 100 |